In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Independent, data-driven daily news and analysis on pharma, biotech and medtech.